Collecting samples to study hairy cell leukemia and develop new cancer treatments
Official title: A Study of Hairy Cell and Other Leukemias With a Focus on Recombinant Immunotoxins for Cancer Treatment
Run by National Institutes of Health Clinical Center (CC) · NCT01087333 · Data updated 2026-11-12
This study is collecting samples from people with hairy cell leukemia and healthy volunteers to see if new treatments can be developed to better fight this type of cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1263 (estimated) |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Drugs / interventions | Moxetumomab, rituximab, trametinib, binimetinib, ibrutinib, chemotherapy |
| Locations | 1 site (Bethesda, Maryland) |
| Status | Recruiting |
| Started | March 2, 2010 |
| Registry record updated | October 29, 2026 |
| Trial ID | NCT01087333 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals aged 18 and older diagnosed with hairy cell leukemia, chronic lymphocytic leukemia, non-Hodgkin's lymphoma, cutaneous T cell lymphoma, or adult T cell lymphoma.
✕Probably not a fit
Patients with no history of hematologic malignancies or solid tumors, as well as those currently pregnant, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to collect clinical samples from patients diagnosed with hairy cell leukemia and other blood cancers, as well as healthy volunteers. Researchers will gather blood, urine, lymph, and tumor tissue samples to analyze the molecular and clinical aspects of these diseases. The study focuses on developing new treatments using recombinant immunotoxins, which are designed to target and kill cancer cells. By comparing samples from leukemia patients and healthy individuals, the study seeks to enhance understanding of these conditions and improve treatment options.
Why it matters
Potential benefit: If successful, this study could lead to the development of more effective treatments for hairy cell leukemia and related blood cancers.
How similar studies have gone: Other studies have shown promise in using immunotoxins for treating hematologic malignancies, indicating a potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: All participants * 18 years of age and older * Desire of the individual to submit data and samples for research * Ability to understand and the willingness to sign a written informed consent document. Individuals with cancer -Participants may have a diagnosis of hematologic malignancy or solid tumor. These participants would not be excluded if they were in long-term complete remission. Normal donors (Individuals without cancer) -Individuals must not have a current or prior diagnosis of a hematologic malignancy or solid tumor. EXCLUSION CRITERIA: All participants -Known pregnancy at enrollment. NOTE: A pregnancy test will be required in individuals on study prior to any procedure done for research purposes that is greater than minimal risk.
Where it's running
-
National Institutes of Health Clinical Center
Bethesda, Maryland, United States Recruiting
Study contacts
- Principal investigator: Robert J Kreitman, M.D. — National Cancer Institute (NCI)
- Study coordinator: Julie C Feurtado, R.N.
- Email: julie.feurtado@nih.gov
- Phone: (301) 480-6186
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ibrutinib and Venetoclax in CLL/SLL: Long-Term Outcomes After Frontline CAPTIVATE
This study follows people with CLL or SLL who previously received the ibrutinib plus venetoclax combination in CAPTIVATE to see how they do over time and what treatments they need if the disease returns.
-
Golidocitinib and chidamide for cutaneous T-cell lymphoma
This study tests whether the combo of golidocitinib and chidamide helps people with CTCL that has already received prior systemic therapy.
-
Impact of Targeted Therapy on Cancer-Related Cognitive Impairment
This study checks whether brain health and well‑being differ for people with leukemia who are starting or on TKI therapy compared with similar individuals without cancer or TKI exposure.
-
BTK degrader plus BCL-2 inhibitor in untreated CLL/SLL
This phase 2 study tests whether the BTK degrader BGB-16673 together with sonrotoclax can help people with newly diagnosed CLL/SLL.
-
Immune profiling during first-line pirtobrutinib treatment for CLL/SLL
This will test pirtobrutinib as a first treatment for adults with CLL or SLL and see how it changes immune cells in the blood and lymph nodes.
-
NX-5948 treatment for adults with CLL or SLL after prior BTK and BCL-2 inhibitor therapy
NX-5948, an oral BTK degrader, will be tried to see if it helps adults with relapsed or refractory CLL or SLL who have already been treated with both BTK and BCL-2 inhibitors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.